Company to host conference call on Monday, October 3rd at 8:30 a.m. ET to discuss new, interim data from the ongoing Phase II AAVIATE® trial

ROCKVILLE, Md., Sept. 26, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting being held September 30-October 3, 2022 in Chicago, IL. The presentations will highlight new and encore data for RGX-314, an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment of wet age-related macular degeneration, diabetic retinopathy and other additional chronic retinal conditions.

Presentations include:

Title: Subretinal RGX-314 Gene Therapy: Phase I/IIa Long-Term Follow-Up Results up to 4 Years
Presenter: Peter A. Campochiaro, M.D., Director, Retinal Cell and Molecular Laboratory, Professor of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine
Date/Time: Saturday, October 1, 2022, 2:25 CDT

Title: Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy: The Phase 2 ALTITUDE Study (encore)
Presenter: Arshad Khanani M.D., M.A, Managing Partner, Director of Clinical Research, Sierra Eye Associates, Clinical Associate Professor, University of Nevada, Reno School of Medicine
Date/Time: Sunday, October 2, 2022, 3:45 CDT

On Monday, October 3 at 8:30 a.m. ET, REGENXBIO also plans to host a conference call to provide a new, interim update from the ongoing Phase II AAVIATE® trial of RGX-314 for the treatment of wet AMD using suprachoroidal delivery. Details for the call will follow.


REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.


Dana Cormack
Corporate Communications 

Chris Brinzey
ICR Westwicke

(PRNewsfoto/REGENXBIO Inc.)


Cision View original content to download multimedia:


Copyright 2022 PR Newswire

Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more REGENXBIO Charts.
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more REGENXBIO Charts.